1. Scrip
  2. >>Advanced Therapies
  3. >>Gene Therapies

Solid Data For Sarepta’s Next-Gen PPMO Treatment But Future Uncertain

 
• By Jessica Merrill

A Phase II study testing a next-generation exon skipping medicine vesleteplirsen in Duchenne muscular dystrophy amendable to exon 51 outpaced Sarepta’s Exondys 51.

path
Sarepta isn't sure about the path ahead for its new exon skipping drug • Source: Shutterstock

Sarepta Therapeutics, Inc.’s next-generation peptide phosphorodiamidate morpholino oligomer (PPMO) treatment SRP-5051, or vesleteplirsen, demonstrated a notable efficacy improvement over the company’s current gold standard for patients with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping, Exondys 51 (eteplirsen), in a Phase II study.

Key Takeaways
  • Vesleteplirsen demonstrated a notable efficacy improvement over Sarepta’s current gold standard for Duchenne muscular dystrophy (DMD), Exondys 51 (eteplirsen), in a Phase II study.

The future development, regulatory and commercial path for vesleteplirsen depends on discussions with regulators about the data and the outcome...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Gene Therapies

Lilly Agrees To Acquire PCSK9 Base-Editing Partner Verve

 
• By Joseph Haas

Instead of opting in on Phase II-ready PCSK9-targeted VERVE-102, Lilly will buy its partner for up to $1.3bn. Analysts call the deal a bargain for Lilly, but fair to Verve.

Sarepta Market Dynamics For Elevidys Imperiled By Second Patient Death

 
• By Joseph Haas

With two deaths in non-ambulatory DMD patients, Sarepta is attempting damage control and will ask the US FDA to advise, setting up a possible confrontation with CBER director Prasad.

Spain’s SpliceBio Secures Sanofi and Roche Support In $135m Financing

 
• By Kevin Grogan

Series B cash will be used to advance its Stargardt disease gene therapy.

New Regenxbio DMD Data Support Gene Therapy Accelerated Approval

 
• By Joseph Haas

Regenxbio reported functional and biomarker data from an ongoing study of RGX-202, which it hopes to file for approval in Duchenne muscular dystrophy in 2026.

More from Advanced Therapies

Spain’s SpliceBio Secures Sanofi and Roche Support In $135m Financing

 
• By Kevin Grogan

Series B cash will be used to advance its Stargardt disease gene therapy.

ASCO: Kite’s Glioblastoma CAR-T Highlights Solid Tumor Progress

 
• By Alaric DeArment

The company presented Phase I data for CART-EGFR-IL13Rα2, showing patient responses in the notoriously hard-to-treat and deadly brain cancer.

Deal Build-Up Amid Early ‘Deep’ Response For IGI’s Trispecific In Myeloma

 
• By Anju Ghangurde

IGI CEO tells Scrip about the “very encouraging” feedback at ASCO to promising early data for the firm's first-in-class investigational trispecific antibody in multiple myeloma. Is a licensing deal in the offing?